MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiology

Background:

• Circulating microRNAs (miRNAs) are investigated as potential biomarkers for acute myocardial infarction (AMI) and disease progression.
• Specific miRNAs, including miRNA-1, miRNA-133, and miRNA-124a, are the focus of research for their diagnostic and prognostic capabilities.

Purpose of the Study:

• To investigate the expression levels of circulating miRNA-1, miRNA-133, and miRNA-124a in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS).
• To compare miRNA expression in STEMI and CS patients against healthy controls.
• To explore correlations between miRNA levels and clinical parameters such as glucose, MMP-9, and soluble ST2.

Main Methods:

• Serum samples were collected from patients diagnosed with STEMI and CS, as well as from control groups.
• Quantitative real-time PCR was used to measure the expression levels of miRNA-1, miRNA-133, and miRNA-124a.
• Statistical analyses were performed to compare miRNA expression between groups and to assess correlations with clinical markers.

Main Results:

• MiRNA-133 was significantly upregulated in both STEMI and CS patients compared to controls.
• MiRNA-124a expression was significantly higher in STEMI and CS patients.
• MiRNA-1 expression differed significantly only in CS patients. Correlations were found between miRNA-1 and glucose, miRNA-133 and MMP-9, and miRNA-124a and soluble ST2.

Conclusions:

• Selected miRNAs (miRNA-124a, miRNA-133) may serve as markers for cardiac injury in STEMI, while all studied miRNAs show potential for marking cardiac injury in CS.
• Despite correlations with certain clinical markers, none of the investigated circulating miRNAs demonstrated predictive value for disease extent, progression, or patient prognosis.
• Circulating miRNAs currently offer no additional benefit over existing markers for myocardial damage assessment.